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Abstract: We isolated a pol inhibitor from the cultured mycelia extract of a fungal strain 
isolated from natural salt from a sea salt pan in Australia, which was identified as   
3-O-methylfunicone by spectroscopic analyses. This compound selectively inhibited the 
activities of mammalian Y-family DNA polymerases (pols) (i.e., pols η, ι and κ). Among 
these pols, human pol κ activity was most strongly inhibited, with an IC50 value of   
12.5 μM. On the other hand, the compound barely influenced the activities of the other 
families of mammalian pols, such as A-family (i.e., pol γ), B-family (i.e., pols α, δ and ε) 
or X-family (i.e., pols β, λ and terminal deoxynucleotidyl transferase), and showed no 
effect on the activities of fish pol δ, plant pols, prokaryotic pols and other DNA metabolic 
enzymes, such as calf primase of pol α, human immunodeficiency virus type-1 (HIV-1) 
reverse transcriptase, human telomerase, T7 RNA polymerase, mouse IMP dehydrogenase 
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(type II), human topoisomerases I and II, T4 polynucleotide kinase or bovine 
deoxyribonuclease I. This compound also suppressed the growth of two cultured human 
cancer cell lines, HCT116 (colon carcinoma cells) and HeLa (cervix carcinoma cells), and 
UV-treated HeLa cells exhibited lower clonogenic survival in the presence of inhibitor. 
 
Keywords: 3-O-methylfunicone; Y-family DNA polymerase; DNA polymerase κ; enzyme 
inhibitor; marine fungal strains; Australian sea salt; anti-cancer drug 
 
1. Introduction 
 
We have long been interested in the integrity of the genome of eukaryotes and its relation to cell 
differentiation. DNA replication, recombination and repair in eukaryotes are key systems to maintain 
these processes [1], and DNA polymerases (pols) have important roles in these. In this regard, we have 
concentrated our efforts on investigating eukaryotic pols associated with these processes [2]. 
The human genome encodes at least 15 pols to carry out cellular DNA synthesis [3,4]. Eukaryotic 
cells contain three replicative pols (α, δ and ε), mitochondrial pol γ, and at least eleven non-replicative 
pols [β, ζ, η, θ, ι, κ, λ, μ, ν, terminal deoxynucleotidyl transferase (TdT) and REV1] [3–5]. Pols have 
a highly conserved structure, which means that their overall catalytic subunits vary, on the whole, very 
little among species. Conserved structures usually indicate important, irreplaceable functions of the 
cell, the maintenance of which provides evolutionary advantages. Based on sequence homology, 
eukaryotic pols can be divided into four main families, A, B, X, and Y [6]. Family A includes 
mitochondrial pol γ, and pols θ and ν, and family B includes three replicative pols (α, δ, and ε) and pol 
ζ. Family X is pols β, λ, μ, and terminal deoxynucleotidyl transferase (TdT), and family Y includes 
pols η, ι, κ, and REV1. Because not all functions of eukaryotic pols have been fully elucidated, 
selective inhibitors of pol families are useful tools for distinguishing pols and clarifying their 
biological functions. We have therefore been searching for natural compounds that selectively inhibit 
each of these eukaryotic pols [7–15], and we succeeded in identifying novel compounds with pol 
inhibitory activity from marine microbiological products [16–19]. 
In this study, we isolated fungal strains from Australian natural sea salt, and obtained 19 strains. 
These marine strains were screened, and a fungal strain displayed inhibitory activity against 
mammalian Y-family pols. The active compound purified from the strain, was identified as   
3-O-methylfunicone, and the potential of this compound as an anti-cancer chemotherapy agent is 
discussed. 
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2. Results and Discussion 
 
2.1. Purification of a DNA Polymerase Inhibitor, 3-O-Methylfunicone (Compound 1), from a Marine 
Fungal Strain 
 
The 19 isolated and purified fungal strains from Australian sea salt were cultured, and each cultured 
mycelium was extracted with chloroform/methanol (v/v 1:1). The extracts were screened for inhibitory 
activity against mammalian pols, and the pol inhibitor (compound 1) was purified by silica gel column 
chromatography from the active mycelium extract of “AF1-2 strain”. From the 
1H- and 
13C-NMR 
spectral data, compound 1 was identified as 3-O-methylfunicone (Figure 1). 
 
Figure 1. Structure of compound 1 (3-O-methylfunicone). 
MeO O
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2.2. Effect of Isolated Compound 1 on the Activities of DNA Polymerases and Other DNA Metabolic 
Enzymes 
 
First, the isolated compound 1 was investigated as to whether it inhibited the activities of ten 
mammalian pols, such as families A (pol γ), B (pols α, δ and ε), X (pols β and λ and TdT), and Y (pols 
η, ι and κ). As shown in Figure 2A, this compound at 100 μM was found to selectively inhibit the 
activity of the Y-family of pols, and within this family pol κ was the most sensitive. Compound 1 
inhibited the activities of these pols dose-dependently, and 50% inhibition of pols η, ι and κ was 
observed at concentrations of 50.1, 34.3 and 12.5 μM, respectively (Figure 3); therefore, the inhibitory 
effect on mammalian Y-family pols ranked as follows: pol κ > pol ι > pol η. On the other hand, the 
other families (i.e., families A, B and X) of mammalian pols, fish pol (cherry salmon pol δ), insect pols 
(fruit fly pols α, δ and ε) hardly influenced the activities (Figure 2A and B), and higher plant pols 
(cauliflower pol α and rice pol λ), and prokaryotic pols (the Klenow fragment of E. coli pol I, T4 pol 
and  Taq pol) had no effect (Figure 2B). When activated DNA (i.e., DNA digested by bovine 
deoxyribonuclease I [DNase I]) and dNTP was used as the DNA template-primer and nucleotide 
substrate instead of synthesized DNA [i.e., poly(dA)/oligo(dT)18] and dTTP, respectively, the 
inhibitory effects of the compound were unchanged (data not shown). 
The same concentration (i.e., 100 μM) of this compound did not influence the activities of other 
DNA metabolic enzymes, such as calf primase pol α, human immunodeficiency virus type-1 (HIV-1) 
reverse transcriptase, human telomerase, T7 RNA polymerase, mouse inosine 5’-monophosphate 
(IMP) dehydrogenase (type II), human topoisomerases I and II, T4 polynucleotide kinase, and bovine 
DNase I (Figure 2C). These results suggest that compound 1 may be a selective inhibitor of 
mammalian Y-family pols in vitro. Mar. Drugs 2009, 7       
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Figure 2. Effect of 3-O-methylfunicone (1) on the activities of various DNA polymerases 
and other DNA metabolic enzymes.  (A) Mammalian pols, (B) fish, insect, plant and 
prokaryotic pols, and (C) other DNA metabolic enzymes. Compound 1 (100 μM) was 
incubated with each enzyme (0.05 units). % of relative activity. Enzymatic activities were 
measured as described in the Experimental section. Activities in the absence of the 
compounds were taken as 100%. Data are shown as the means ± SEM of four independent 
experiments. 
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Figure 3. Mammalian Y-family DNA polymerase inhibition dose-response curves of   
3-O-methylfunicone (1). Compound 1 was incubated with human pol η (square), mouse 
pol ι (triangle), and human pol κ (circle) (0.05 units of each). Pol activity was measured as 
described in the Experimental section. Activity in the absence of the compounds was taken 
as 100%. Data are shown as the means ± SEM of three independent experiments. 
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2.3. Mode of DNA Pol κ Inhibition by Compound 1 
 
Next, to elucidate the mechanism of inhibition, the extent of inhibition as a function of DNA 
template-primer or dNTP substrate concentrations was studied (Figure 4). In kinetic analysis, 
poly(dA)/oligo(dT)18 and dTTP were used as the DNA template-primer and dNTP substrate, 
respectively. Double reciprocal plots of the results showed that compound 1 induced inhibition of 
human pol κ activity was competitive with the DNA template-primer and non-competitive with the 
dNTP substrate (Figure 4A and B). In the case of the DNA template-primer, the apparent maximum 
velocity (Vmax) was unchanged at 52.6 pmol/h, whereas the 295, 467, and 812% increases in Michaelis 
constant (Km) were observed in the presence of 4, 8, and 12 μM of compound 1, respectively (Figure 
4A). The Km for the dNTP substrate was 2.00 μM, and the Vmax for the dNTP substrate decreased from 
41.7 to 11.1 pmol/h in the presence of 12 μM compound 1 (Figure 4B). The inhibition constant (Ki) 
value, obtained from Dixon plots, was found to be 1.3 and 4.4 μM for the DNA template-primer and 
dTTP substrate, respectively (Figure 4C and D). When activated DNA and four dNTP substrates were 
used as the DNA template-primer and dNTP substrate, respectively, the inhibition of human pol κ by 
compound 1 was competitive with the DNA template-primer and non-competitive with the dNTP 
substrate (data not shown). These results suggest that compound 1 directly binds to the DNA template-
primer-binding site of pol κ, whereas this compound may bind or interact with a site that is distinct 
from the dNTP substrate-binding site. 
On the other hand, the inhibition of family B pols, such as pols α, δ and ε, by aphidicolin, which is 
a known classic pol inhibitor, was uncompetitive with activated DNA as a DNA template-primer and 
competitive with respect to the dNTP substrate [20]. Moreover, aphidicolin inhibited pol α by Mar. Drugs 2009, 7       
 
 
629
competing with dCTP but not by competing with the other three deoxynucleoside triphosphates [20]. 
In contrast, inhibition of pol κ by compound 1 was non-competitive with the four deoxynucleoside 
triphosphates (data not shown). The mode of the inhibitory effect of compound 1 on Y-family pols was 
quite different from the mode of the inhibitory effect of aphidicolin on B-family pols. 
 
Figure 4. Kinetic analysis of the inhibition of human pol κ by compound 1. (A) Human pol 
κ activity was measured in the absence (closed square) or presence of 4 μM (closed circle), 
8  μM (closed triangle) or 12 μM (closed diamond) compound 1 using the indicated 
concentrations of the DNA template-primer. (B) Human pol κ activity was assayed with 
the indicated concentrations of the substrate dTTP in the presence of 4 μM (open circle),  
8  μM (open triangle) or 12 μM (open diamond) or in the absence (open square) of 
compound 1. (C) and (D) The inhibition constants (Ki) were determined as 1.3 and 4.4 μM 
from a Dixon plot made on the basis of the same data for (A) and (B), respectively. 
Amount of human pol κ in the assay mixture was 0.05 units. 
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2.4. Inhibitory Effect of Isolated Compound 1 on Cultured Human Cancer Cells 
 
Pols have recently emerged as important cellular targets for chemical intervention in the 
development of anti-cancer agents. The isolated compound 1 could therefore be useful in Mar. Drugs 2009, 7       
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chemotherapy, and we investigated the growth inhibitory effect of this compound against two human 
cancer cell lines, a colon carcinoma cell line, HCT116, and a cervix carcinoma cell line, HeLa. 
As shown in Figure 5A, compound 1 dose-dependently suppressed both HCT116 and HeLa cancer 
cell growth, and the LD50 value was 63.8 and 63.3 μM, respectively. Since the LD50 value of 
compound 1 for HCT116 cells was almost the same as that for HeLa cells, compound 1 might suppress 
all human cancer cell growth. The cell growth inhibition dose was approximately 1.3 to 5.1-fold higher 
than the enzyme inhibitory concentration, suggesting that the cause of the cancer cell influence might 
be the activity of pols. On the other hand, compound 1 did not influence the cell proliferation and 
growth of human normal cells such as HUVEC (human umbilical vein endothelial cells) and HDF 
(human dermal fibroblast) (data not shown); therefore, this compound might be a selective anti-cancer 
chemotherapy agent. 
 
Figure 5. (A) Human cancer cell growth inhibition dose-response curves of 3-O-methyl-
funicone (1). Various concentrations (0 to 150 μM) of compound 1 were incubated with 
human colon carcinoma (HCT116) cells (circle) and human cervix carcinoma (HeLa) cells 
(square) for 24 h. Rate of cell growth was determined by MTT assay [44] as described in 
the Experimental section. Data are shown as the means ± SEM of five independent 
experiments. (B) Clonogenic survival of UV-treated HeLa cells by compound 1. Various 
concentrations (0 to 100 μM) of compound 1 were incubated with 10 J/m
2 UV-treated 
(closed circle) or untreated (open circle) HeLa cells. After 7 days, the number of colonies 
in each treatment group was counted. Values are the means ± SEM of two independent 
experiments. 
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Y-family pols differ from other families in having low fidelity on undamaged templates and in their 
ability to replicate through damaged DNA. Members of this family are hence called translesion 
synthesis (TLS) pols [21]. Depending on the lesion, TLS pols can bypass the damage in an error-free 
or error-prone fashion, the latter resulting in elevated mutagenesis. Xeroderma pigmentosum variant 
(XPV) patients, for instance, have mutations in the gene encoding pol η, which is error-free for UV Mar. Drugs 2009, 7       
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lesions. In XPV patients, alternative error-prone pols, e.g. pol ζ (B-family pol), are thought to be 
involved in mistakes which result in the cancer predisposition of these patients. Other members in 
humans are pols ι, κ, and Rev1 [6,21]. In E. coli, two TLS pols, pol IV (DINB) and pol V (UMUC), 
are known [21]. 
As shown in Figure 5B, compound 1 significantly enhanced HeLa cell UV-sensitivity, and the 
inhibiting clonogenic survival effect of 100 μM of the compound on 10 J/m
2 UV exposed cells was 
4.3-fold stronger than that on non-exposed cells. The LD50 value of compound 1 for UV-treated cell 
growth had the same potency as the IC50 values for mammalian Y-family pols. These results suggested 
that compound 1 inhibited the activities of family Y pols needed for DNA repair, thereby DNA 
damage must be augmented by this compound and UV-treatment, and then the cancer cells might 
undergo apoptotic cell death. It has been reported that pol η-deficient human fibroblast cells generated 
using siRNA were more than 3-fold sensitive to UV and DNA-targeting anticancer agents [22]. This 
supports the idea that compound 1 might selectively inhibit the activity of Y-family pols in the cells 
and that inhibitors of Y-family pols may have potential as anti-cancer drugs for clinical radiation 
therapy or cancer chemotherapy. 
 
3. Conclusions 
 
We obtained 3-O-methylfunicone (1) from a marine fungal strain isolated from Australian sea salt 
and showed it was a potent inhibitor specific to both mammalian Y-family pols and human cancer cell 
growth. Compound 1 has extremely high specificity for mammalian pol families, and significantly 
suppressed UV-treated human cancer cell growth and clonogenic survival. This compound could be a 
useful molecular tool as a Y-family pol-specific inhibitor in studies to determine the precise roles of 
the pol family in vitro. The products isolated from marine fungal strains, such as compound 1, may 
provide valuable information for developing a drug design strategy for anti-cancer chemotherapy 
agents.  
 
4. Experimental 
 
4.1. Isolation and Cultivation of Marine Fungal Strains from Australian Sea Salt 
 
Natural salt (75 g) from an Australian sea salt pan was dissolved in distilled water (300 mL), and 
the saturated solution was filtered through a membrane filter (ADVANTEC, 0.2 μm, 47 mm). The 
filtered solution was placed on a corn meal agar (CMA) plate (Sigma-Aldrich K. K., Tokyo, Japan) 
containing rose Bengal (Junnsei Chemical Co., Ltd., Tokyo, Japan), and this plate was cultured for  
1–2 weeks at 25 ºC. Each grown mycelium on the plate was transferred to individual potato dextrose 
agar (PDA) (Difco Lab., KS, USA) plates, and cultured at 28 ºC for 10 days. Each cultured fungus was 
transferred to a new PDA plate, and cultured at 28 ºC for 10 days. Transformation and culture on PDA 
plates was repeated two to five times to obtain pure mycelium strains. The number of isolated and 
purified fungal strains was 19, which were stored at –80 ºC (Figure 6, left). 
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Figure 6. (Left) Isolation methods of marine fungal strains from Australian sea salt. 
(Right) Purification procedure of a compound with pol inhibitory activity from mycelia of 
“AF1-2” fungal strain. 
 
 
4.2. Extraction and Purification of Compound from Marine Fungal Strains 
 
The 19 isolated marine fungal strains were cultured in liquid potato dextrose (PD) medium, and 
each mycelium was extracted with chloroform/methanol (v/v 1:1). After evaporation of the solvent, the 
extracts were screened for inhibitory activity against mammalian pols. Pol catalyzes the addition of 
deoxyribonucleotides to the 3’-hydroxyl terminus of primed double-stranded DNA molecules and the 
assay method of pol inhibitors is shown in Figure 7. The mycelium extract of strain “AF1-2” displayed 
the greatest ability to inhibit DNA polymerase activity. An image of the AF1-2 fungal strain is shown 
in Figure 8. This strain was precultured by transferring a small agar piece to a 3L Erlenmeyer flask 
containing PD (2.4 g) in H2O (100 mL), and then fermented under static conditions in the dark for  
3 days. The production culture was initiated by transferring the preculture to production medium [PD 
(2.4 g) and Daigo’s artificial seawater (36 g; Wako Chemical. Co. Ltd., Tokyo, Japan) in H2O (1 L)], 
and fermentation was carried out at room temperature under static conditions in the dark for 41 days. 
As shown in Figure 6 (right), the harvested fungal mycelia of AF1-2 were filtered from the cultured 
broth through cheesecloth, followed by homogenization in EtOAc, and extraction under static 
conditions at room temperature for 10 days. The extract was evaporated in vacuo to obtain crude 
residue (778 mg), and was separated by silica gel column chromatography (n-hexane/EtOAc = 8/1 to 
1/2) to give fractions 1–10. Active fraction no. 6 was purified by a 2nd silica gel column 
chromatography (100% CHCl3 to 100% MeOH) to afford the active compound 1 (49 mg). 
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Figure 7. Assay method of pol inhibitor. 
 
 
Figure 8. Marine fungal strain AF1-2. 
 
 
4.3. Structure Determination of Isolated Compound 
 
1H- and 
13C-NMR were recorded on a Bruker DRX400 instrument. Chemical shifts are reported in 
δ, parts per million (ppm), relative to TMS as an internal standard. Mass spectra were obtained on an 
API QSTAR Pulsar i spectrometer. The molecular formula of compound 1 was determined to be 
C20H20O8 by the high resolution mass spectrum. From the 
1H- and 
13C-NMR spectral data, compound 
1 was identified as 3-O-methylfunicone (Figure 1). These spectroscopic data were consistent with 
those previously reported [23]. The analyzed data of compound 1 are shown below: 
3-O-Methylfunicone (1). Colorless amorphous solid; 
1H-NMR (CDCl3) δ: 8.49 (1H, d, J = 0.4 Hz), 
7.09 (1H, d, J = 2.4 Hz), 6.64 (1H, d, J = 2.4 Hz), 6.61 (1H, dq, J =16.0,   
6.4 Hz), 6.54 (1H, ddd, J = 16.0, 1.2, 0.4 Hz), 3.86 (3H, s), 3.81 (3H, s), 3.78 (3H s), 3.73 (3H, s), 1.97 
(3H, dd, J = 6.4, 1.2 Hz); 
13C-NMR (CDCl3) δC: 191.8, 172.4, 166.4, 160.7, 159.1, 157.3, 154.6, 144.1, 
134.9, 129.7, 126.3, 126.1, 118.4, 105.2, 102.9, 60.5, 56.0, 55.5, 52.3, 18.9; HR ESIMS m/z 411.1058 
[M+Na]
+ (calcd for 411.1055). 
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4.4. Materials 
 
Natural salt from a sea salt pan in Australia was supplied by the Research Institute of Salt and Sea 
Water Science (Kanagawa, Japan). Nucleotides, such as [
3H]-deoxythymidine 5'-triphosphate (dTTP) 
(43 Ci/mmol), and chemically synthesized DNA template, such as poly(dA), were purchased from GE 
Healthcare Bio-Sciences (Little Chalfont, UK). DNA primer, such as oligo(dT)18, was customized by 
Sigma-Aldrich K. K. (Hokkaido, Japan). All other reagents were of analytical grade and were 
purchased from Wako Chemical Industries (Osaka, Japan). 
 
4.5. Enzymes 
 
Pol α was purified from calf thymus by immuno-affinity column chromatography, as described by 
Tamai et al. [24]. Recombinant rat pol β was purified from E. coli JMpβ5, as described by Date et al. 
[25]. The human pol γ catalytic gene was cloned into pFastBac. Histidine-tagged enzyme was 
expressed using the BAC-TO-BAC HT Baculovirus Expression System according to the supplier's 
manual (Life Technologies, MD, USA) and purified using ProBoundresin (Invitrogen Japan, Tokyo, 
Japan) [26]. Human pols δ and ε were purified by nuclear fractionation of human peripheral blood 
cancer cells (Molt-4) using the second subunit of pols δ and ε-conjugated affinity column 
chromatography, respectively [27]. A truncated form of human pol η (residues 1–511) tagged with 
His6 at its C-terminal was expressed in E. coli cells and purified as described by Kusumoto et al. [28]. 
A recombinant mouse pol ι tagged with His6 at its C-terminal was expressed and purified by Ni-NTA 
column chromatography as described elsewhere (Masutani et al., in preparation). A truncated form of 
pol κ (residues 1–560) with 6 x His-tags attached at the C-terminus was overproduced in E. coli and 
purified as described by Ohashi et al. [29]. Recombinant human His-pol λ was overexpressed and 
purified according to a method described by Shimazaki et al. [30]. Fish pol δ was purified from the 
testis of cherry salmon (Oncorhynchus masou) [31]. Fruit fly pols α, δ and ε were purified from early 
embryos of Drosophila melanogaster, as described by Aoyagi et al. [32,33]. Pol α from a higher plant, 
cauliflower inflorescence, was purified according to the methods outlined by Sakaguchi et al. [34]. 
Recombinant rice (Oryza sativa L. cv. Nipponbare) His-pol λ was overexpressed and purified 
according to a method described by Uchiyama et al. [35]. Calf thymus TdT and bovine pancreas 
DNase I were obtained from Stratagene Cloning Systems (La Jolla, CA, USA). HIV-1 reverse 
transcriptase (recombinant) and the Klenow fragment of pol I from E. coli were purchased from 
Worthington Biochemical Corp. (Freehold, NJ, USA). T4 pol, Taq pol, T7 RNA polymerase and T4 
polynucleotide kinase were purchased from Takara Bio (Tokyo, Japan). Purified human placenta DNA 
topoisomerases I and II were purchased from TopoGen, Inc. (Columbus, OH, USA). 
 
4.6. DNA Polymerase Assays 
 
The reaction mixtures for pol α, pol β, plant pols and prokaryotic pols were described previously 
[7,8]; those for pol γ, and pols δ and ε were as described by Umeda et al. [26] and Ogawa et al. [36], 
respectively. The reaction mixtures for pols η, ι and κ were the same as for pol α, and the reaction 
mixture for pol λ was the same as for pol β. For pols, poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP were Mar. Drugs 2009, 7       
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used as the DNA template-primer and nucleotide (i.e., dNTP) substrate, respectively. For HIV-1 
reverse transcriptase, poly(rA)/oligo(dT)18 (A/T = 2/1) and dTTP were used as the DNA template-
primer and nucleotide substrate, respectively. For TdT, oligo(dT)18 (3'-OH) and dTTP were used as the 
DNA primer and nucleotide substrate, respectively. 
The compounds were dissolved in distilled dimethyl sulfoxide (DMSO) at various concentrations 
and sonicated for 30 sec. Aliquots of 4 μl sonicated samples were mixed with 16 μl of each enzyme 
(final amount 0.05 units) in 50 mM Tris-HCl (pH7.5) containing 1 mM dithiothreitol, 50% glycerol 
and 0.1 mM EDTA, and kept at 0 °C for 10 min. These inhibitor-enzyme mixtures (8 μl) were added to 
16 μl of each of the enzyme standard reaction mixtures (final concentration of 50 mM Tris-HCl [pH 
7.5], 1 mM dithiothreitol, 1 mM MgCl2, 15% glycerol, 10 μM poly(dA)/oligo(dT)18 and 10 μM [
3H]-
dTTP), and incubation was carried out at 37 °C for 60 min, except for Taq pol, which was incubated at 
74 °C for 60 min. Activity without the inhibitor was considered 100%, and the remaining activity at 
each concentration of the inhibitor was determined relative to this value. One unit of pol activity was 
defined as the amount of enzyme that catalyzed the incorporation of 1 nmol dNTP (i.e., dTTP) into 
synthetic DNA template-primers in 60 min at 37 °C under the normal reaction conditions for each 
enzyme [7,8]. 
 
4.7. Other DNA Metabolic Enzymes Assays 
 
The activities of calf primase of pol α, human telomerase, T7 RNA polymerase, mouse IMP 
dehydrogenase, human DNA topoisomerases I and II, T4 polynucleotide kinase and bovine DNase I 
were measured in standard assays according to the manufacturer's specifications, as described by 
Tamiya-Koizumi et al. [37], Oda et al. [38], Nakayama et al. [39], Mizushina et al. [40], Ishimaru  
et al. [41], Soltis et al. [42] and Lu et al. [43], respectively. 
 
4.8. Investigation of Growth on Cultured Human Cancer Cells 
 
Human colon carcinoma cell line, HCT116, was a kind gift from Dr. Bert Vogelstein (Johns 
Hopkins University, Baltimore, MO, USA). Human cervix carcinoma cell line, HeLa, was obtained 
from Health Science Research Resources Bank (Osaka, Japan). The cells were maintained in McCoy's 
5A medium supplemented with 10% FBS, sodium bicarbonate (2 g/L) and streptomycin (100 μg/mL). 
The cells were cultured at 37 °C in standard medium in a humidified atmosphere of 5% CO2-95% air. 
The cytotoxicity of the compound was investigated as follows: high concentrations (10 mM) of the 
compounds were dissolved in DMSO and stored. Approximately 5 x 10
3 cells per well were inoculated 
in 96-well micro plates, then the compound stock solution was diluted to various concentrations, and 
applied to each well. After incubation for 24 h, the survival rate was determined by MTT   
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay [44].  
 
4.9. UV-Treated Clonogenic Assay 
 
For clonogenic assay, 600 cells of HeLa were seeded on 10-cm plates and allowed to grow for 24 h 
before 10 J/m
2 UV irradiation treatment. The cells were then treated with various concentrations of Mar. Drugs 2009, 7       
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compound 1 for 24 h. The cells were then washed with PBS and fresh medium was added for an 
additional 7-day incubation in a humidified 10% CO2 incubator at 37 °C. After 7 days, the cultured 
cells were stained with 0.5% methylene blue in 50% ethanol to visualize the colonies. The number of 
colonies in each treatment group was counted, and the cell survival data were presented as percentage 
of the colony numbers of treated/untreated cells. 
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